Needham analyst Mike Matson raised his price target on Surmodics (SRDX) to $74 and kept his Buy rating after its Q3 earnings beat and raised FY18 outlook. The analyst anticipates accelerating revenue growth with more upside to consensus estimates coming from the company’s new products such as the .014” and .018″ balloon dilation catheters and Telemark microcatheter, along with its deferred revenue associated with the Abbott (ABT) agreement milestones.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.